About Us
Founded in 2016, JY BioMedical transitioned from health supplements to biotechnology and pharmaceutical research in 2020, expanding its expertise and market potential. The company specializes in personalized medicine, using dendritic cells (DCs) and MSC-derived exosomes to enhance immune responses against cancer. Their therapies, including DC cancer vaccines and Gamma-Delta T cell treatments, offer precise, broad-spectrum anti-tumor activity. Additionally, MSC-based products support regenerative medicine, promoting tissue repair and immune modulation. With a strong R&D focus, JY BioMedical develops innovative therapies for cancer, ocular diseases, and skin regeneration, pushing medical frontiers to improve patient care.
Science
JY BioMedical specializes in personalized medicine, utilizing dendritic cells (DCs) and MSC-derived exosomes to boost the immune response against cancer. Our DC cancer vaccines train T cells to specifically target tumor cells, minimizing rejection risk. Our Gamma-Delta T cell therapies offer broad-spectrum anti-tumor activity, effectively targeting various malignancies. Additionally, our MSC-derived products support regenerative medicine by promoting tissue repair and modulating immune responses. We also advance precision oncology with our Antibody Drug Conjugate (Anti-CEACAM6 Heavy Chain Ab), which selectively delivers cytotoxic agents to CEACAM6-overexpressing tumors, enhancing treatment efficacy while protecting healthy tissues.
News
